| Old Articles: <Older 1481-1490 Newer> |
|---|
 |
The Motley Fool
October 21, 2004
Brian Gorman |
Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.   |
Technology Research News
October 20, 2004
Eric Smalley |
Biochip spots single viruses A detector recently built from nanowire transistors can identify individual virus particles in real time in unpurified samples. Labs-on-a-chip based on the device could be used to monitor diseases. |
Technology Research News
October 20, 2004
Eric Smalley |
Wide laser makes simple tweezers Much of medical diagnostics and biomedical research involves trapping, manipulating and sorting individual cells and like-sized bits of matter. A recently demonstrated way of manipulating cells promises to be less expensive than laser tweezers. |
Bio-IT World
October 14, 2004
Mark D. Uehling |
Not-So-Cool DNA Storage With robotics and innovative sample tagging, GenVault offers DNA archiving with no freezer burn. |
Bio-IT World
October 14, 2004
Kevin Davies |
Galileo Opts for Illumina Beads Following a successful gene-mapping partnership with one California high-tech company, Montreal-based Galileo Genomics is turning to another to finish the job. |
Bio-IT World
October 14, 2004
Robert M. Frederickson |
Nanosphere Strikes Gold Recently, scientists at Nanosphere developed a colorimetric method for DNA detection that obviates the need for target or signal amplification. |
The Motley Fool
October 19, 2004
Rich Duprey |
Chiron Crisis Creates Investor Opportunity As flu vaccine maker flames out, other companies may step in to fill the void. |
The Motley Fool
October 18, 2004
W.D. Crotty |
An Odyssey of Wealth Destruction If anything could have gone wrong at Odyssey Healthcare, it did. If it weren't for a Department of Justice investigation, the company would be a bargain. For now, the company is worth watching. |
The Motley Fool
October 18, 2004
Charly Travers |
Biotech's 5-Baggers How can yesterday's biotech winners lead you to today's top performers? |
BusinessWeek
October 25, 2004
Gene G. Marcial |
Par: Out Of The Rough? Since posting disappointing earnings in April, Par Pharmaceutical, No. 6 in U.S. generic drugs, has seen its shares plummet from 61 to 34. |
| <Older 1481-1490 Newer> Return to current articles. |
